For the quarter ending 2026-03-31, ANVS had -$5,313,257 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -17,606,382 | -9,834,412 | -7,262,658 | -11,757,127 |
| Stock-based compensation expense | 182,823 | 356,524 | 444,647 | 996,505 |
| Change in fair value of warrants | -268,000 | 296,000 | -20,000 | -418,000 |
| Prepaid expenses and other current assets | 475,335 | -353,275 | -2,421,723 | 950,568 |
| Accounts payable | 2,685,152 | 478,490 | 1,137,715 | -1,331,663 |
| Accrued expenses | 6,470,118 | -576,912 | -209,042 | 255,800 |
| Net cash used in operating activities | -9,011,624 | -8,927,035 | -3,487,615 | -13,205,053 |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net | - | 34,598,126 | - | - |
| Proceeds from issuance of common stock, net | - | - | 1,643,728 | 19,783,423 |
| Proceeds from exercise of common stock options, net | - | 1,999 | - | - |
| Proceeds from issuance of common stock, and warrants, net | 3,698,367 | - | - | - |
| Net cash provided by financing activities | 3,698,367 | 13,172,974 | 1,643,728 | 19,783,423 |
| Net (decrease) increase in cash and cash equivalents | -5,313,257 | 4,245,939 | -1,843,887 | 6,578,370 |
| Cash and cash equivalents, beginning of period | 19,532,338 | 15,286,399 | 10,551,916 | - |
| Cash and cash equivalents, end of period | 14,219,081 | 19,532,338 | 15,286,399 | - |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)